Immunosuppressive therapy in ocular cicatricial pemphigoid

Area of Science:

• Ophthalmology
• Immunology
• Dermatology

Background:

• Ocular cicatricial pemphigoid (OCP) is a chronic autoimmune blistering disease affecting the conjunctiva.
• Long-term treatment efficacy of systemic immunosuppressive drugs for OCP requires further investigation.

Purpose of the Study:

• To evaluate the efficacy of systemic immunosuppressive drugs, including corticosteroids, in the long-term treatment of ocular cicatricial pemphigoid.
• To assess the natural course and progression patterns of untreated OCP.

Main Methods:

• A prospective clinical trial involving 57 patients with OCP.
• Patients were assigned to five groups: control, cyclophosphamide and prednisone, cyclophosphamide alone, azathioprine, or prednisone alone.
• Long-term follow-up was conducted to assess treatment efficacy and disease progression.

Main Results:

• Untreated OCP exhibits a variable course, not always progressing, and can be asymmetric in severity and progression.
• Immunosuppressive therapy, including corticosteroids, inhibited conjunctival shrinking in all treatment groups.
• Despite treatment, some patients in all groups experienced disease progression, and serious complications were observed.

Conclusions:

• Systemic immunosuppressive drugs demonstrate potential in managing OCP by reducing conjunctival shrinking.
• Treatment efficacy varies, and disease progression can occur even with immunosuppression.
• Careful monitoring for disease progression and potential adverse effects is crucial in OCP management.